Publication Date
2-27-2025
Journal
Morbidity and Mortality Weekly Report
DOI
10.15585/mmwr.mm7406a2
PMID
40014791
PMCID
PMC11867582
PubMedCentral® Posted Date
2-27-2025
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Influenza Vaccines, United States, Influenza, Human, Adolescent, Child, Adult, Child, Preschool, Infant, Young Adult, Middle Aged, Seasons, Aged, Hospitalization, Vaccine Efficacy
Abstract
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness–associated outpatient visits and hospitalizations from four VE networks during the 2024–25 influenza season (October 2024–February 2025). Among children and adolescents aged <18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged ≥18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024–2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged ≥6 months as long as influenza viruses continue to circulate locally.
Included in
Community Health and Preventive Medicine Commons, Diseases Commons, Infectious Disease Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, Medical Sciences Commons, Pediatrics Commons